Related Experiment Video
Updated: Aug 7, 2025
Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
Published on: June 16, 2023
Choroid plexus-targeted NKCC1 overexpression to treat post-hemorrhagic hydrocephalus
Cameron Sadegh1, Huixin Xu2, Jason Sutin3
1Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Insights
Post-hemorrhagic hydrocephalus (PHH) is a dangerous CSF buildup after brain bleeds. Activating the NKCC1 transporter in the choroid plexus helps clear fluid, offering a potential gene therapy target for this condition.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Research
Background:
- Post-hemorrhagic hydrocephalus (PHH) is a critical complication following intraventricular hemorrhage (IVH).
- Current treatments for PHH primarily involve neurosurgical interventions.
- The underlying mechanisms of PHH progression and effective therapeutic targets remain incompletely understood.
Purpose of the Study:
- To investigate the role of the Na-K-Cl cotransporter 1 (NKCC1) in the choroid plexus (ChP) in mitigating PHH.
- To explore the potential of gene therapy using adeno-associated virus (AAV)-NKCC1 for treating PHH.
Main Methods:
- Induction of IVH in a model system by intraventricular blood infusion.
- Monitoring of cerebrospinal fluid (CSF) potassium levels and ChP epithelial cell activity.
- Administration of ChP-targeted AAV-NKCC1 to assess its therapeutic efficacy.
- Evaluation of ventriculomegaly and CSF clearance capacity.
Main Results:
- Intraventricular blood increased CSF [K+] and activated ChP NKCC1.
- ChP-targeted AAV-NKCC1 delivery successfully prevented blood-induced ventriculomegaly.
- AAV-NKCC1 treatment led to sustained enhancement of CSF clearance capacity.
- An inactive NKCC1 variant (AAV-NKCC1-NT51) did not mitigate ventriculomegaly.
Conclusions:
- Intraventricular hemorrhage triggers a CSF clearance mechanism dependent on ChP NKCC1.
- Targeted gene therapy with AAV-NKCC1 shows promise for treating PHH.
- NKCC1 activation is a crucial factor in managing intracranial fluid accumulation after hemorrhage.
Abstract:
Post-hemorrhagic hydrocephalus (PHH) refers to a life-threatening accumulation of cerebrospinal fluid (CSF) that occurs following intraventricular hemorrhage (IVH). An incomplete understanding of this variably progressive condition has hampered the development of new therapies beyond serial neurosurgical interventions. Here, we show a key role for the bidirectional Na-K-Cl cotransporter, NKCC1, in the choroid plexus (ChP) to mitigate PHH. Mimicking IVH with intraventricular blood led to increased CSF [K+] and triggered cytosolic calcium activity in ChP epithelial cells, which was followed by NKCC1 activation. ChP-targeted adeno-associated viral (AAV)-NKCC1 prevented blood-induced ventriculomegaly and led to persistently increased CSF clearance capacity. These data demonstrate that intraventricular blood triggered a trans-choroidal, NKCC1-dependent CSF clearance mechanism. Inactive, phosphodeficient AAV-NKCC1-NT51 failed to mitigate ventriculomegaly. Excessive CSF [K+] fluctuations correlated with permanent shunting outcome in humans following hemorrhagic stroke, suggesting targeted gene therapy as a potential treatment to mitigate intracranial fluid accumulation following hemorrhage.
